CLDF Title
Home | Contact Us | Bookmark
  HBV   HCC   HCV   HE   NASH   PBC   THROMBOCYTOPENIA
About CLDF
Board of Trustees Board of Advisors/Faculty 2018 GI Fellow Board of Advisors
Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
HE-Single Disease Content  
Live CME Meetings

Hepatic Encephalopathy:
The Pathway to Quality Care

The initiative will be tailored to the specific needs of hospital-based health care professionals.

Complications of Cirrhosis: Strategies to Improve Long-Term Patient Outcomes

This activity was developed for primary care physicias and health care professionals in the primary care field who manage patients with cirrhosis and wish to improve standard practice of care.
Webcasts
     
Hepatology News Tonight   CME Webcast
Outpatient Challenges in HE   CME Webcast
Complications of Cirrhosis: Strategies to Improve Long-Term Patient Outcomes-Part 1   CME Webcast
Complications of Cirrhosis: Strategies to Improve Long-Term Patient Outcomes-Part 2   CME Webcast
Selected Hepatic Encephalopathy Abstracts from AASLD 2017 Presented by
Catherine Frenette, MD
   CME Webcast
Selected Hepatic Encephalopathy Abstracts from AASLD 2017 Presented by
Kimberly Brown, MD
   CME Webcast
Inpatient management of Hepatic Encephalopathy
   CME Webcast
Future treatments in HE: What to hope for and what to expect
   CME Webcast
Selected Hepatic Encephalopathy Abstracts from AASLD 2017 Presented by
Nancy Reau, MD
   CME Webcast
Gut-Liver-Brain Axis: A Translational Perspective
   CME Webcast
Selected Hepatic Encephalopathy Abstracts from AASLD 2017 Presented by
Vinod Rustgi, MD
   CME Webcast
Hepatic Encephalopathy-Who is at risk, how to treat, and how to maintain treatment   CME Webcast
Selected Hepatic Encephalopathy Abstracts from AASLD 2016 - Presented by Nancy Reau, MD   Educational Webcast
Managing an Important Complication of Cirrhosis: Hepatic Encephalopathy - Presented by Steven Flamm, MD   Educational Webcast
Selected Hepatic Encephalopathy Abstracts from AASLD 2016 - Presented by Robert Brown, MD   Educational Webcast
Selected Hepatic Encephalopathy Abstracts from AASLD 2016 - Presented by Douglas Dieterich, MD   Educational Webcast
Recoginizing an Important Complication of Cirrhosis: Hepatic Encephalopathy - Presented by Bruce Bacon, MD   Educational Webcast
Selected Hepatic Encephalopathy Abstracts from AASLD 2016 - Presented by Kim Brown, MD   Educational Webcast
Update on Hepatic Encephalopathy and the Feasibility of Broad Implementation of AASLD Guidelines   Educational Webcast
Hepatic Encephalopathy: Economic and Social Burden, Hospital Readmission and Cognition   Educational Webcast
Xpert Perspectives on the Complication on Cirrhosis: Year-End Review 2015   CME Webcast
Improving Mortality in Cirrhosis: Preventing Bleeding, Encephalopathy and Infection - John Vierling   Educational Webcast
Patients with Cirrhosis: Managing the HCV Peri-Transplant Patient - Fred Poordad   Educational Webcast
Patients with Cirrhosis: Managing Hepatic Encephalopathy and Other Complications   Educational Webcast
Portal vein thrombosis (PVT) in compensated cirrhosis: A prospective cohort study on 898 patients   Educational Webcast
Nosocomial Index Infections Portend Worse Outcomes Compared to Health-Care Associated Index Infections in a Multi-Center Hospitalized Cirrhosis Cohort (NACSELD)   Educational Webcast
Correction of Hyponatremia with Tolvaptan therapy is associated with Improved Cognition, Quality of Life, Reduced Caregiver Burden and Brain Edema on MRI in Cirrhosis   Educational Webcast
Portal vein thrombosis (PVT) in compensated cirrhosis: A prospective cohort study on 898 patients   Educational Webcast
A Cost Effectiveness of Rifaximin in the Treatment of Hepatic Encephalopathy   Educational Webcast
A prospective, double-blind, randomized placebo-controlled trial of carvedilol for early primary prophylaxis of esophageal varices in cirrhosis   Educational Webcast
Cirrhosis and the complications of portal hypertension   Educational Webcast
Using the EncephalApp Stroop to Screen for Covert Hepatic Encephalopathy   Educational Webcast
EncephalApp Stroop Download and Instructions   Educational Webcast
Stroop App Demonstration   Educational Webcast
Transient Elastography is a Useful Clinical Tool to Detect Minimal Hepatic Encephalopathy in a Cohort of Compensated Cirrhotic Patients   Educational Webcast
Albumin for Acute Episodic Hepatic Encephalopathy (Alfae Study)   Educational Webcast
Rifaximin Improves Cognition and Endotoxemia in Minimal Hepatic Encephalopathy by Shifting Gut Microbial Functionality Without Altering their Abundance   Educational Webcast
AST-120 (Spherical Carbon Adsorbent) in Covert Hepatic Encephalopathy: Results of the Astute Trial   Educational Webcast
A Genetic Variant in the Promoter of Phosphate Activated Glutaminase (GLS) Gene Predicts the Risk of Developing Hepatic Encephalopathy   Educational Webcast
Prognostic Benefit of the Addition of an Electroencephalographic (EEG) Index to the MELD Score: The MELD-EEG   Educational Webcast
Spleno-Systemic Shunts and Covert HE   Educational Webcast
Hepatic Encephalopathy is an Independent Risk Factor for Mortality in Patients Awaiting Liver Transplantation   Educational Webcast
 
Dynamic CME Resource Library
     
Hepatic Encephalopathy Update: Reports from the 64th Annual Meeting of the American Association for the Study of Liver Diseases   Educational eNewsletter
Hepatic Encephalopathy Update: Reports from the 2013 American College of Gastroenterology Meeting   Educational eNewsletter
Hepatic Encephalopathy Update: Reports From the 2013 Digestive Disease Week Annual Meeting   Educational eNewsletter
Hepatic Encephalopathy Update: Reports from the 2013 International Liver Conference   Educational eNewsletter
Hepatic Encephalopathy: A Review of Diagnostic Methods   Educational eNewsletter
 
Slide Library
HE Slides
   Released: 2018
test
Hepatology News Tonight: Managing Complication of Cirrhosis
57 slides
 
 
   Released: 2017
Webcast
Complications of Cirrhosis: Strategies to Improve Long-term Patient Outcomes
46 slides
 
 
   Released: 2016
Webcast
Current And Future Treatment Options For PBC, Nash And Hepatic Encephalopathy
75 slides
 
 
   Released: 2015
Webcast
Current Dilemmas in the Management of Cirrhosis
38 slides
 
 
   Released: 2014
Webcast
Liver Summit 2014
12 slides
 
 
   Released: 2014
Webcast
Improving Mortality in Cirrhosis: Preventing Bleeding, Encephalopathy and Infection
43 slides
 
 
   Released: 2014
Webcast
Patients with Cirrhosis: Managing the HCV Peri-Transplant Patient
40 slides
 
 
   Released: 2013
Webcast
Current Insights into the Management of Hepatic Encephalopathy
65 slides
 
 
   Released: 2013
Webcast
Cirrhosis and the complications of portal hypertension
40 slides
 
 
   Released: 2013
Webcast
Using the EncephalApp Stroop to Screen for Covert Hepatic Encephalopathy
63 slides
 
 
   Released: 2013
Webcast
HE Highlights from EASL 2013
63 slides
 
 
 
 
Abstract Library
  1. Quality of life in patients with minimal hepatic encephalopathy
    Ridola L1, Nardelli S2, Gioia S2, Riggio O2. World J Gastroenterol. 2018 Dec 28;24(48):5446-5453. doi: 10.3748/wjg.v24.i48.5446.


  2. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)
    Montagnese S1, Russo FP2, Amodio P3, Burra P2, Gasbarrini A4, Loguercio C5, Marchesini G6, Merli M7, Ponziani FR4, Riggio O7, Scarpignato C8. Dig Liver Dis. 2018 Dec 12. pii: S1590-8658(18)31274-X. doi: 10.1016/j.dld.2018.11.035. [Epub ahead of print]


  3. Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy
    Labenz C1,2, Toenges G3, Schattenberg JM1,2, Nagel M1,2, Sprinzl MF1,2, Nguyen-Tat M1,2, Zimmermann T1,2, Huber Y1,2, Marquardt JU1,2, Galle PR1,2, Wörns MA1,2. J Clin Gastroenterol. 2018 Nov 14. doi: 10.1097/MCG.0000000000001149. [Epub ahead of print]


  4. MHE Testing in Real World Scenario
    Lauridsen MM1, Vilstrup H2. J Clin Exp Hepatol. 2018 Dec;8(4):438-440. doi: 10.1016/j.jceh.2018.04.010. Epub 2018 May 5.


  5. Current Diagnosis and Classification of Hepatic Encephalopathy
    Amodio P1. J Clin Exp Hepatol. 2018 Dec;8(4):432-437. doi: 10.1016/j.jceh.2018.07.001. Epub 2018 Jul 11.


  6. The role of Branched Chain Amino Acids in the treatment of hepatic Encephalopathy
    Dam G1, Aamann L1, Vistrup H1, Gluud LL2. J Clin Exp Hepatol. 2018 Dec;8(4):448-451. doi: 10.1016/j.jceh.2018.06.004. Epub 2018 Jun 27.


  7. Diet and the Role of Food in Common Gastrointestinal Diseases
    Pearlman M1, Akpotaire O2. Med Clin North Am. 2019 Jan;103(1):101-110. doi: 10.1016/j.mcna.2018.08.008.


  8. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
    Hudson M1,2, Schuchmann M3. Eur J Gastroenterol Hepatol. 2018 Nov 15. doi: 10.1097/MEG.0000000000001311. [Epub ahead of print]


  9. Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing
    Duarte-Rojo A1, Allampati S2, Thacker LR3, Flud CR1, Patidar KR4, White MB4, Klair JS1, Heuman DM4, Wade JB5, Gavis EA4, Bajaj JS6. Metab Brain Dis. 2018 Nov 30. doi: 10.1007/s11011-018-0350-z. [Epub ahead of print]


  10. Valproic acid induced acute liver injury resulting in hepatic encephalopathy- a case report and literature review
    Gayam V1, Mandal AK1, Khalid M1, Shrestha B1, Garlapati P1, Khalid M2. J Community Hosp Intern Med Perspect. 2018 Oct 15;8(5):311-314. doi: 10.1080/20009666.2018.1514933. eCollection 2018.


  11. Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS)
    Sturm L1, Bettinger D1,2, Giesler M1, Boettler T1, Schmidt A1, Buettner N1, Thimme R1, Schultheiss M1. United European Gastroenterol J. 2018 Nov;6(9):1380-1390. doi: 10.1177/2050640618795928. Epub 2018 Aug 15.


  12. Hepatic encephalopathy: Sometimes more portal than hepatic
    Aller MA1, Arias N2,3, Blanco-Rivero J4, Arias JL3,5, Arias J1. J Gastroenterol Hepatol. 2018 Oct 21. doi: 10.1111/jgh.14514. [Epub ahead of print]


  13. Frailty, Psychoactive Medications, and Cognitive Dysfunction are Associated with Poor Patient-Reported Outcomes in Cirrhosis
    Tapper EB1, Baki J1, Parikh ND1, Lok AS1. Hepatology. 2018 Nov 1. doi: 10.1002/hep.30336. [Epub ahead of print]


  14. Effects of branched chain amino acid supplementation on patient care outcomes in adults and children with liver cirrhosis: A systematic review
    Ooi PH1, Gilmour SM2, Yap J2, Mager DR3. Clin Nutr ESPEN. 2018 Dec;28:41-51. doi: 10.1016/j.clnesp.2018.07.012. Epub 2018 Aug 14.


  15. Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Butterworth RF1, Kircheis G2, Hilger N3, McPhail MJW4. J Clin Exp Hepatol. 2018 Sep;8(3):301-313. doi: 10.1016/j.jceh.2018.05.004. Epub 2018 May 22.


  16. Hyperammonemia in Hepatic Encephalopathy
    Jayakumar AR1,2, Norenberg MD3,4,5. J Clin Exp Hepatol. 2018 Sep;8(3):272-280. doi: 10.1016/j.jceh.2018.06.007. Epub 2018 Jun 20.


  17. Periodontal Therapy Favorably Modulates the Oral-Gut-Hepatic Axis in Cirrhosis
    Bajaj JS1, Matin P2, White MB, Fagan A3, Golob Deeb J4, Acharya C5, Dalmet SS6, Sikaroodi M7, Gillevet PM7, Sahingur SE8. Am J Physiol Gastrointest Liver Physiol. 2018 Aug 17. doi: 10.1152/ajpgi.00230.2018. [Epub ahead of print]


  18. EASL Clinical Practice Guidelines on nutrition in chronic liver disease
    Merli M, Berzigotti A, Zelber-Sagi S, Dasarathy S, Montagnese S, Genton L, Plauth M, Parés A. J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32177-9. doi: 10.1016/j.jhep.2018.06.024. [Epub ahead of print]


  19. Cerebral Blood Flow and Metabolism in Hepatic Encephalopathy-A Meta-Analysis
    Bjerring PN1,2, Gluud LL2, Larsen FS1. J Clin Exp Hepatol. 2018 Sep;8(3):286-293. doi: 10.1016/j.jceh.2018.06.002. Epub 2018 Jun 20.


  20. Pathogenesis of Hepatic Encephalopathy in Chronic Liver Disease
    Ochoa-Sanchez R1, Rose CF1. J Clin Exp Hepatol. 2018 Sep;8(3):262-271. doi: 10.1016/j.jceh.2018.08.001. Epub 2018 Aug 18.


  21. Race and Gradient Difference Are Associated with Increased Risk of Hepatic EncephalopathyHospital Admission After Transjugular Intrahepatic Portosystemic Shunt Placement
    Rowley MW1,2, Choi M3, Chen S4,2, Hirsch K4,2, Seetharam AB5,2. J Clin Exp Hepatol. 2018 Sep;8(3):256-261. doi: 10.1016/j.jceh.2017.12.003. Epub 2017 Dec 30.


  22. Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients' Experience on Rifaximin-? (PROSPER): an observational study among 550 patients
    Krag A1, Schuchmann M2, Sodatonou H3, Pilot J3, Whitehouse J4, Strasser SI5, Hudson M6. Hepatol Med Policy. 2018 Jan 8;3:4. doi: 10.1186/s41124-017-0029-9. eCollection 2018.


  23. Proton pump inhibitors are associated to minimal and overt hepatic encephalopathy and increase mortality in cirrhotics.
    Nardelli S1, Gioia S1, Ridola L1, Farcomeni A1,2, Merli M1, Riggio O1. Hepatology. 2018 Oct 5. doi: 10.1002/hep.30304. [Epub ahead of print]


  24. Rifaximin has the potential to prevent complications of cirrhosis
    Flamm SL1, Mullen KD2, Heimanson Z3, Sanyal AJ4. Therap Adv Gastroenterol. 2018 Sep 28;11:1756284818800307. doi: 10.1177/1756284818800307. eCollection 2018.


  25. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy
    Flamm SL1. Am J Med Sci. 2018 Sep;356(3):296-303. doi: 10.1016/j.amjms.2018.06.008. Epub 2018 Jun 19.


  26. Olfactory Function is Affected in Patients with Cirrhosis Depending on the Severity of Hepatic Encephalopathy
    Heiser C1, Haller B2, Sohn M3, Hofauer B1, Knopf A2, Mühling T4, Freiherr J5, Bender M4, Tiller M4, Schmidt A4, Schepp W4, Gundling F. Ann Hepatol. 2018 Aug 24;17(5):822-829. doi: 10.5604/01.3001.0012.3143.


  27. Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index
    Tapper EB1,2, Konerman M1, Murphy S3,4, Sonnenday CJ5. Am J Transplant. 2018 Jul 18. doi: 10.1111/ajt.15020. [Epub ahead of print]


  28. Evaluation of the cost-effectiveness of rifaximin-? for the management of patients with hepatic encephalopathy in the United Kingdom
    Berni E1, Murphy D2, Whitehouse J2, Conway P1, Di Maggio P2, Currie CJ1,3, Poole C4. Curr Med Res Opin. 2018 Aug 13:1-8. doi: 10.1080/03007995.2018.1499506. [Epub ahead of print]


  29. Current Management of Hepatic Encephalopathy
    Acharya C1, Bajaj JS2. Am J Gastroenterol. 2018 Jul 13. doi: 10.1038/s41395-018-0179-4. [Epub ahead of print]


  30. Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
    Neff G1, Zachry W 3rd2. Pharmacoeconomics. 2018 Jul;36(7):809-822. doi: 10.1007/s40273-018-0641-6.


  31. Coil-Assisted Retrograde Transvenous Obliteration (CARTO): An Alternative Treatment Option for Refractory Hepatic Encephalopathy
    Lee EW1,2, Saab S, Kaldas F3,4, Fletcher S5, Busuttil RW3,4, Durazo F3,6, McWilliams JP5, DiNorcia J 3rd3,4, Padia SA5, Kee ST5. Am J Gastroenterol. 2018 Aug;113(8):1187-1196. doi: 10.1038/s41395-018-0109-5. Epub 2018 Jun 14.


  32. Hepatic encephalopathy: current challenges and future prospects
    Swaminathan M1, Ellul MA2, Cross TJ1. Hepat Med. 2018 Mar 22;10:1-11. doi: 10.2147/HMER.S118964. eCollection 2018.


  33. Why and when to measure ammonemia in cirrhosis?
    Mallet M1, Weiss N2, Thabut D1, Rudler M3. Clin Res Hepatol Gastroenterol. 2018 Mar 15. pii: S2210-7401(18)30031-7. doi: 10.1016/j.clinre.2018.01.004. [Epub ahead of print]


  34. Refractory Hepatic Encephalopathy After Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors and Outcomes with Revision
    Rowley MW1,2, Choi M3, Chen S4,2, Hirsch K4,2, Seetharam AB5,6. Cardiovasc Intervent Radiol. 2018 Jun 5. doi: 10.1007/s00270-018-1992-2. [Epub ahead of print]


  35. Patient Acceptance of Lactulose Varies Between Indian and American Cohorts: Implications for Comparing and Designing Global Hepatic Encephalopathy Trials
    Rathi S1, Fagan A2, Wade JB3, Chopra M1, White MB2, Ganapathy D2, Acharya C2, Dhiman RK1, Bajaj JS2. J Clin Exp Hepatol. 2018 Jun;8(2):109-115. doi: 10.1016/j.jceh.2017.11.010. Epub 2017 Dec 2.


  36. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases
    Bajaj JS1, Barbara G2, DuPont HL3, Mearin F4, Gasbarrini A5, Tack J6. Dig Liver Dis. 2018 Aug;50(8):741-749. doi: 10.1016/j.dld.2018.04.020. Epub 2018 Apr 27.


  37. Liver-Microbiome Axis in Health and Disease
    Adolph TE1, Grander C1, Moschen AR1, Tilg H2.


  38. Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests
    Tapper EB1,2,3, Parikh ND1,2,3, Waljee AK1,2,3, Volk M4, Carlozzi NE5, Lok AS1,2. Am J Gastroenterol. 2018 Apr;113(4):529-538. doi: 10.1038/ajg.2018.6. Epub 2018 Mar 13.


  39. Considerations for the cost-effective management of hepatic encephalopathy
    Flamm SL1. Am J Manag Care. 2018 Mar;24(4 Suppl):S51-S61.


  40. Management of Hepatic Encephalopathy Not Responsive to First-Line Treatments
    Nardelli S1, Ridola L2, Gioia S3, Riggio O3. Curr Treat Options Gastroenterol. 2018 Jun;16(2):253-259. doi: 10.1007/s11938-018-0183-1.


  41. Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis is Restored by Fecal Transplant
    Bajaj JS1, Kakiyama G1, Savidge T2, Takei H3, Kassam ZA4, Fagan A1, Gavis EA1, Pandak WM1, Nittono H3, Hylemon PB1, Boonma P2, Haag A2, Heuman DM1, Fuchs M1, John B1, Sikaroodi M5, Gillevet PM5. Hepatology. 2018 Apr 17. doi: 10.1002/hep.30037. [Epub ahead of print]


  42. Acute-on-Chronic Liver Failure: Getting ready for prime-time
    Bajaj JS1, Moreau R2, Kamath PS3, Vargas HE4, Arroyo V5, Reddy KR6, Szabo G7, Tandon P8, Olson J9, Karvellas C8, Gustot T10, Lai JC11, Wong F12. Hepatology. 2018 Apr 24. doi: 10.1002/hep.30056. [Epub ahead of print]


  43. Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?
    Koretz RL1,2. Am J Gastroenterol. 2018 Jun 19. doi: 10.1038/s41395-018-0138-0. [Epub ahead of print]


  44. Coil-Assisted Retrograde Transvenous Obliteration (CARTO): An Alternative Treatment Option for Refractory Hepatic Encephalopathy
    Lee EW1,2, Saab S, Kaldas F3,4, Fletcher S5, Busuttil RW3,4, Durazo F3,6, McWilliams JP5, DiNorcia J 3rd3,4, Padia SA5, Kee ST5. Am J Gastroenterol. 2018 Jun 14. doi: 10.1038/s41395-018-0109-5. [Epub ahead of print]


  45. Critical flicker frequency test predicts overt hepatic encephalopathy and survival in patients with liver cirrhosis
    Barone M1, Shahini E1, Iannone A1, Viggiani MT1, Corvace V2, Principi M1, Di Leo A3. Dig Liver Dis. 2018 May;50(5):496-500. doi: 10.1016/j.dld.2018.01.133. Epub 2018 Jan 31.


  46. Refractory Hepatic Encephalopathy After Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors and Outcomes with Revision
    Rowley MW1,2, Choi M3, Chen S4,2, Hirsch K4,2, Seetharam AB5,6. Cardiovasc Intervent Radiol. 2018 Jun 5. doi: 10.1007/s00270-018-1992-2. [Epub ahead of print]


  47. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases
    Bajaj JS1, Barbara G2, DuPont HL3, Mearin F4, Gasbarrini A5, Tack J6. Dig Liver Dis. 2018 Apr 27. pii: S1590-8658(18)30717-5. doi: 10.1016/j.dld.2018.04.020. [Epub ahead of print]


  48. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathyin people with cirrhosis
    Goh ET1, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. Cochrane Database Syst Rev. 2018 May 15;5:CD012410. doi: 10.1002/14651858.CD012410.pub2.


  49. Acute-on-Chronic Liver Failure: Getting ready for prime-time
    Bajaj JS1, Moreau R2, Kamath PS3, Vargas HE4, Arroyo V5, Reddy KR6, Szabo G7, Tandon P8, Olson J9, Karvellas C8, Gustot T10, Lai JC11, Wong F12. Hepatology. 2018 Apr 24. doi: 10.1002/hep.30056. [Epub ahead of print]


  50. Development of a novel clinical staging model for cirrhosis using the Nationwide Inpatient Sample
    Haj M1, Hart M1, Rockey DC1. J Investig Med. 2018 May 14. pii: jim-2018-000709. doi: 10.1136/jim-2018-000709. [Epub ahead of print]


  51. Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis is Restored by Fecal Transplant
    Bajaj JS1, Kakiyama G1, Savidge T2, Takei H3, Kassam ZA4, Fagan A1, Gavis EA1, Pandak WM1, Nittono H3, Hylemon PB1, Boonma P2, Haag A2, Heuman DM1, Fuchs M1, John B1, Sikaroodi M5, Gillevet PM5. Hepatology. 2018 Apr 17. doi: 10.1002/hep.30037. [Epub ahead of print]


  52. Management of Hepatic Encephalopathy Not Responsive to First-Line Treatments
    Nardelli S1, Ridola L2, Gioia S3, Riggio O3. Curr Treat Options Gastroenterol. 2018 Jun;16(2):253-259. doi: 10.1007/s11938-018-0183-1.


  53. Hepatic encephalopathy: Diagnosis and management
    Amodio P1. Liver Int. 2018 Apr 6. doi: 10.1111/liv.13752. [Epub ahead of print]


  54. Covert hepatic encephalopathy leads to distinct alterations in the emotional state, independently of MELD-Score
    Greinert R#, Ripoll C, Zipprich A#.Z Gastroenterol. 2018 Jan 16. doi: 10.1055/s-0043-123766. [Epub ahead of print]


  55. Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy
    Gadiparthi C1, Cholankeril G2, Yoo ER3, Hu M4, Wong RJ5, Ahmed A6,7. Dig Dis Sci. 2018 Apr 2. doi: 10.1007/s10620-018-5032-5. [Epub ahead of print]


  56. Hepatic encephalopathy: current challenges and future prospects
    Swaminathan M1, Ellul MA2, Cross TJ1. Hepat Med. 2018 Mar 22;10:1-11. doi: 10.2147/HMER.S118964. eCollection 2018.


  57. Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests
    Tapper EB1,2,3, Parikh ND1,2,3, Waljee AK1,2,3, Volk M4, Carlozzi NE5, Lok AS1,2. Am J Gastroenterol. 2018 Mar 13. doi: 10.1038/ajg.2018.6. [Epub ahead of print]


  58. Why and when to measure ammonemia in cirrhosis?
    Mallet M1, Weiss N2, Thabut D1, Rudler M3. Clin Res Hepatol Gastroenterol. 2018 Mar 15. pii: S2210-7401(18)30031-7. doi: 10.1016/j.clinre.2018.01.004. [Epub ahead of print]


  59. Prevalence of restless legs syndrome in a tertiary cohort of ambulant patients with chronic liver disease
    Ma MX1, Huang Y1,2, Adams LA1,2, Gilpin R1, Garas G1,2, MacQuillan G1,2, Jeffrey GP1,2, Nicholas RM1. Intern Med J. 2018 Mar;48(3):347-350. doi: 10.1111/imj.13719.


  60. Interventions to improve physical function and prevent adverse events in cirrhosis
    Trivedi HD1, Tapper EB2. Gastroenterol Rep (Oxf). 2018 Feb;6(1):13-20. doi: 10.1093/gastro/gox042. Epub 2018 Jan 10.


  61. Gut?:?liver?:?brain axis: the microbial challenge in the hepatic encephalopathy
    Mancini A1, Campagna F2, Amodio P2, Tuohy KM1. Food Funct. 2018 Feb 27. doi: 10.1039/c7fo01528c. [Epub ahead of print]


  62. The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies
    Ridola L1, Cardinale V1, Riggio O2. Ann Gastroenterol. 2018 Mar-Apr;31(2):151-164. doi: 10.20524/aog.2018.0232. Epub 2018 Feb 1.


  63. Considerations for the cost-effective management of hepatic encephalopathy
    Flamm SL1. Am J Manag Care. 2018 Mar;24(4 Suppl):S51-S61.


  64. Assessment of the Spectrum of Hepatic Encephalopathy: A Multi-Center Study
    Reuter B1, Walter K2, Bissonnette J3, Leise MD4, Lai J5, Tandon P6, Kamath PS4, Biggins SW2, Rose CF3, Wade JB1, Bajaj JS1. Liver Transpl. 2018 Feb 19. doi: 10.1002/lt.25032. [Epub ahead of print]


  65. Reducing recurrent hospital admissions in patients with decompensated cirrhosis
    Aspinall RJ1. Br J Hosp Med (Lond). 2018 Feb 2;79(2):93-96. doi: 10.12968/hmed.2018.79.2.93.


  66. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis
    Cao Q1, Yu CB1, Yang SG1, Cao HC1, Chen P1, Deng M1, Li LJ2. Hepatobiliary Pancreat Dis Int. 2018 Feb;17(1):9-16. doi: 10.1016/j.hbpd.2018.01.005. Epub 2018 Feb 2.


  67. Effects of Alcohol on the Brain in Cirrhosis: Beyond Hepatic Encephalopathy
    Davis BC1, Bajaj JS1. Alcohol Clin Exp Res. 2018 Feb 8. doi: 10.1111/acer.13605. [Epub ahead of print]


  68. Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin
    Reigadas E1,2,3, Alcalá L1,3,4, Gómez J1, Marín M1,2,3,4, Martin A1,3, Onori R1, Muñoz P1,2,3,4, Bouza E1,2,3,4. Clin Infect Dis. 2017 Oct 23. doi: 10.1093/cid/cix918. [Epub ahead of print]


  69. Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis
    Schepis F1, Vizzutti F2, Garcia-Tsao G3, Marzocchi G4, Rega L5, De Maria N6, Di Maira T6, Gitto S6, Caporali C4, Colopi S4, De Santis M4, Arena U7, Rampoldi A8, Airoldi A9, Cannavale A10, Fanelli F10, Mosconi C11, Renzulli M11, Agazzi R12, Nani R12, Quaretti P13, Fiorina I13, Moramarco L13, Miraglia R14, Luca A14, Bruno R15, Fagiuoli S16, Golfieri R11, Torricelli P4, Di Benedetto F17, Saverio Belli L9, Banchelli F18, Laffi G7, Marra F19, Villa E6. Clin Gastroenterol Hepatol. 2018 Jan 25. pii: S1542-3565(18)30097-1. doi: 10.1016/j.cgh.2018.01.029. [Epub ahead of print]


  70. Effect of Post-Traumatic Stress Disorder on Cognitive Function and Covert Hepatic Encephalopathy Diagnosis in Cirrhotic Veterans
    Burroughs TK1, Wade JB2, Ellwood MS1, Fagan A3, Heuman DM3, Fuchs M3, Bajaj JS4. Dig Dis Sci. 2018 Jan 8. doi: 10.1007/s10620-017-4894-2. [Epub ahead of print]


  71. Lactulose: A Simple Sugar in a Complex Encephalopathy
    Wijdicks EFM1. Neurocrit Care. 2018 Jan 2. doi: 10.1007/s12028-017-0494-4. [Epub ahead of print]


  72. The emergency medicine evaluation and management of the patient with cirrhosis
    Long B1, Koyfman A2. Am J Emerg Med. 2017 Dec 23. pii: S0735-6757(17)31049-5. doi: 10.1016/j.ajem.2017.12.047. [Epub ahead of print]


  73. Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study
    Weiss N1,2,3,4,5,6,7,8, Tripon S1,2,3,4,5,6,7,8, Lodey M, Guiller E, Junot H, Monneret D1,2,3,4,5,6,7,8, Mayaux J, Brisson H, Mallet M1,2,3,4,5,6,7,8, Rudler M1,2,3,4,5,6,7,8, Imbert-Bismut F1,2,3,4,5,6,7,8, Thabut D1,4; Brain-Liver Pitié-Salpêtrière Study Group (BLIPS). Fundam Clin Pharmacol. 2017 Dec 14. doi: 10.1111/fcp.12340. [Epub ahead of print]


  74. Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
    Roggeri DP1, Roggeri A1. Hepat Med. 2017 Sep 25;9:37-43. doi: 10.2147/HMER.S146438. eCollection 2017.


  75. A Risk Score to Predict the Development of Hepatic Encephalopathy in a Population-Based Cohort of Patients with Cirrhosis
    Tapper EB1,2, Parikh N1,2, Sengupta N3, Mellinger J1, Ratz D4, Lok AS1, Su GL1,2. Hepatology. 2017 Nov 1. doi: 10.1002/hep.29628. [Epub ahead of print]


  76. The impact of rifaximin-? on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS)
    Hudson M1, Radwan A2, Di Maggio P2, Cipelli R3, Ryder SD4, Dillon JF5, Cash WJ6, Przemioslo RT7, Wright M8, Shawcross DL9, Jalan R10, Saksena S11, Allison M12, Richardson P13, Farrington E14, Aspinall RJ15. Frontline Gastroenterol. 2017 Oct;8(4):243-251. doi: 10.1136/flgastro-2016-100792. Epub 2017 Apr 7.


  77. Recent advances in hepatic encephalopathy
    Liere V#1, Sandhu G#2, DeMorrow S1,3. F1000Res. 2017 Sep 4;6:1637. doi: 10.12688/f1000research.11938.1. eCollection 2017.


  78. An educational tool for the prophylaxis of hepatic encephalopathy
    Garrido M1, Turco M1, Formentin C1, Corrias M1, De Rui M1, Montagnese S1, Amodio P1. BMJ Open Gastroenterol. 2017 Sep 11;4(1):e000161. doi: 10.1136/bmjgast-2017-000161. eCollection 2017.


  79. Lactulose enemas in the treatment of hepatic encephalopathy. Do we help or harm?
    de Lorenzo-Pinto A1, García-Sánchez R2, Lorenzo-Salinas A3. Rev Esp Enferm Dig. 2017 Sep 18;109. doi: 10.17235/reed.2017.5106/2017. [Epub ahead of print]


  80. A pilot evaluation of a computer-based psychometric test battery designed to detect impairment in patients with cirrhosis
    Cook NA1, Kim JU1, Pasha Y1, Crossey MM1, Schembri AJ2,3, Harel BT2,4, Kimhofer T5, Taylor-Robinson SD1. Int J Gen Med. 2017 Sep 6;10:281-289. doi: 10.2147/IJGM.S140197. eCollection 2017.


  81. Brain Microstructural Abnormalities in Patients With Cirrhosis Without Overt Hepatic Encephalopathy: A Voxel-Based Diffusion Kurtosis Imaging Study
    Chen HJ1, Liu PF2, Chen QF2, Shi HB3. AJR Am J Roentgenol. 2017 Aug 16:1-8. doi: 10.2214/AJR.17.17827. [Epub ahead of print]


  82. Electro-Radiological Observations of Grade III/IV Hepatic EncephalopathyPatients with Seizures
    Newey CR1,2, George P3, Sarwal A4, So N5, Hantus S3,5. Neurocrit Care. 2017 Aug 8. doi: 10.1007/s12028-017-0435-2. [Epub ahead of print]


  83. Ammonia Levels and Hepatic Encephalopathy in Patients with Known Chronic Liver Disease
    Ninan J1, Feldman L2. J Hosp Med. 2017 Aug;12(8):659-661. doi: 10.12788/jhm.2794.


  84. A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis
    Tandon P1, Reddy KR2, O'Leary JG3, Garcia-Tsao G4, Abraldes JG1, Wong F5, Biggins SW6, Maliakkal B7, Fallon MB8, Subramanian RM9, Thuluvath P10, Kamath PS11, Thacker LR12, Bajaj JS12; North American Consortium for the Study of End-Stage Liver Disease. Hepatology. 2017 Jan;65(1):217-224. doi: 10.1002/hep.28900. Epub 2016 Nov 29.


  85. Optimal treatment of hepatic encephalopathy
    Allampati S1, Mullen KD. Minerva Gastroenterol Dietol. 2016 Dec;62(4):296-304. Epub 2016 Oct 20.


  86. Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis
    Liu TL1, Trogdon J2, Weinberger M3,4, Fried B5, Barritt AS 4th6. Dig Dis Sci. 2016 Nov;61(11):3335-3345. Epub 2016 Aug 1.


  87. Epilepsy as a risk factor for hepatic encephalopathy in patients with cirrhosis: a cohort study
    Jepsen P1,2, Christensen J3, Weissenborn K4, Watson H5, Vilstrup H6. BMC Gastroenterol. 2016 Jul 26;16(1):77. doi: 10.1186/s12876-016-0487-3.


  88. Electroencephalogram variability in patients with cirrhosis associates with the presence and severity of hepatic encephalopathy
    Olesen SS1, Gram M2, Jackson CD3, Halliday E4, Sandberg TH2, Drewes AM5, Morgan MY4. J Hepatol. 2016 Sep;65(3):517-23. doi: 10.1016/j.jhep.2016.05.004. Epub 2016 May 13.


  89. Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients
    Thomas KL1, La AQ, Punia S, Doroudgar S, Perry PJ. Ann Clin Psychiatry. 2016 Feb;28(1):37-42.


  90. Hepatic Encephalopathy: Pharmacological Therapies Targeting Ammonia
    Rahimi RS1, Rockey DC2. Semin Liver Dis. 2016 Feb;36(1):48-55. doi: 10.1055/s-0036-1571298. Epub 2016 Feb 12.


  91. A low-cost, user-friendly electroencephalographic recording system for the assessment of hepatic encephalopathy
    Schiff S1, Casa M1, Di Caro V1, Aprile D1, Spinelli G1, De Rui M1, Angeli P1, Amodio P1, Montagnese S1. Hepatology. 2016 May;63(5):1651-9. doi: 10.1002/hep.28477. Epub 2016 Mar 2.


  92. Techniques for Transjugular Intrahepatic Portosystemic Shunt Reduction and Occlusion
    Taylor AG1, Kolli KP2, Kerlan RK Jr2. Tech Vasc Interv Radiol. 2016 Mar;19(1):74-81. doi: 10.1053/j.tvir.2016.01.008. Epub 2016 Jan 29.


  93. Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients
    Barboza KC1, Salinas LM2, Sahebjam F2, Jesudian AB3, Weisberg IL4, Sigal SH2. Metab Brain Dis. 2016 Mar 31. [Epub ahead of print]


  94. Cognitive Impairment Predicts The Occurrence Of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt
    Nardelli S1, Gioia S1, Pasquale C1, Pentassuglio I1, Farcomeni A1,2, Merli M1, Salvatori FM1,3, Nikolli L1, Torrisi S1, Greco F1, Nicoletti V1, Riggio O1. Am J Gastroenterol. 2016 Mar 1. doi: 10.1038/ajg.2016.29. [Epub ahead of print]


  95. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial
    Schulz C1,2, Schütte K3, Kropf S4, Schmitt FC5, Vasapolli R6, Kliegis LM7, Riegger A8, Malfertheiner P9. Trials. 2016 Feb 29;17(1):111. doi: 10.1186/s13063-016-1205-8.


  96. A low-cost, user-friendly EEG recording system for the assessment of hepatic encephalopathy
    Sami S1, Mariella C1, Valeria DC1, Daniele A1, Giuseppe S1, Michele R1, Paolo A1, Piero A1, Sara M1. Hepatology. 2016 Feb 2. doi: 10.1002/hep.28477. [Epub ahead of print]


  97. The why and wherefore of hepatic encephalopathy
    Grover VP1, Tognarelli JM1, Massie N1, Crossey MM1, Cook NA1, Taylor-Robinson SD1. Int J Gen Med. 2015 Dec 16;8:381-90. doi: 10.2147/IJGM.S86854. eCollection 2015.


  98. In Patients with Cirrhosis, Driving Simulator Performance is Associated With Real-life Driving
    Lauridsen MM1, Thacker LR2, White MB1, Unser A1, Sterling RK1, Stravitz RT1, Matherly S1, Puri P1, Sanyal AJ1, Gavis EA1, Luketic V1, Siddiqui MS1, Heuman DM1, Fuchs M1, Bajaj JS3. Clin Gastroenterol Hepatol. 2015 Nov 18. pii: S1542-3565(15)01547-5. doi: 10.1016/j.cgh.2015.11.007. [Epub ahead of print]


  99. Probiotics are Helpful in Hepatic Encephalopathy: A Meta-Analysis of Randomized Trials
    Saab S1,2, Suraweera D3, Au J4, Saab E1, Alper T1, Tong MJ1,2,5. Liver Int. 2015 Nov 12. doi: 10.1111/liv.13005. [Epub ahead of print]


  100. Clinical science workshop: targeting the gut-liver-brain axis
    Patel VC1, White H1, Støy S1, Bajaj JS2, Shawcross DL3. Metab Brain Dis. 2015 Oct 8. [Epub ahead of print]


  101. Qualifying and quantifying minimal hepatic encephalopathy
    Morgan MY1, Amodio P2, Cook NA3, Jackson CD4, Kircheis G5, Lauridsen MM6, Montagnese S2, Schiff S2, Weissenborn K7. Metab Brain Dis. 2015 Sep 28. [Epub ahead of print]


  102. What is new about diet in hepatic encephalopathy
    Merli M1, Iebba V2, Giusto M3. Metab Brain Dis. 2015 Sep 29. [Epub ahead of print]


  103. Comprehensive Care of Patients with Chronic Liver Disease
    James J1, Liou IW2. Med Clin North Am. 2015 Sep;99(5):913-33. doi: 10.1016/j.mcna.2015.05.001. Epub 2015 Jul 2.


  104. MODULATION OF GABAA RECEPTORS BY NEUROSTEROIDS. A NEW CONCEPT TO IMPROVE COGNITIVE AND MOTOR ALTERATIONS IN HEPATIC ENCEPHALOPATHY
    Agusti A1, Llansola M2, Hernández-Rabaza V2, Cabrera-Pastor A2, Montoliu C1, Felipo V3. J Steroid Biochem Mol Biol. 2015 Aug 22. pii: S0960-0760(15)30052-2. doi: 10.1016/j.jsbmb.2015.08.020. [Epub ahead of print]


  105. Current diagnosis and management of post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) refractory hepatic encephalopathy
    Pereira K1, Carrion AF2, Martin P2, Vaheesan K2, Salsamendi J1, Doshi M1, Yrizarry JM1. Liver Int. 2015 Sep 1. doi: 10.1111/liv.12956. [Epub ahead of print]


  106. Resting-state functional connectivity abnormalities correlate with psychometric hepatic encephalopathy score in cirrhosis
    Chen HJ1, Jiang LF2, Sun T3, Liu J3, Chen QF4, Shi HB5. Eur J Radiol. 2015 Aug 18. pii: S0720-048X(15)30078-4. doi: 10.1016/j.ejrad.2015.08.005. [Epub ahead of print]


  107. Altered metal metabolism in patients with HCV-related cirrhosis and hepatic
    Marano M1, Vespasiani Gentilucci U, Altamura C, Siotto M, Squitti R, Bucossi S, Quintiliani L, Migliore S, Greco F, Scarciolla L, Quattrocchi CC, Picardi A, Vernieri F. Metab Brain Dis. 2015 Aug 27. [Epub ahead of print]


  108. Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients
    Jepsen P1, Watson H2, Andersen PK3, Vilstrup H4. J Hepatol. 2015 Jul 20. pii: S0168-8278(15)00470-5. doi: 10.1016/j.jhep.2015.07.007. [Epub ahead of print]


  109. New Methods of Testing and Brain Imaging in Hepatic Encephalopathy: A Review
    Edula RG1, Pyrsopoulos NT2. Clin Liver Dis. 2015 Aug;19(3):449-59. doi: 10.1016/j.cld.2015.04.001. Epub 2015 May 23.


  110. Varices and Variceal Hemorrhage in Cirrhosis. A new view of an old problem
    Garcia-Tsao G1, Bosch J2. Clin Gastroenterol Hepatol. 2015 Jul 17. pii: S1542-3565(15)00970-2. doi: 10.1016/j.cgh.2015.07.012. [Epub ahead of print]


  111. The Clinical Relevance of Minimal Hepatic Encephalopathy - A Critical Look
    Weissenborn K1. Dig Dis. 2015;33(4):555-61. doi: 10.1159/000375348. Epub 2015 Jul 6.


  112. Diagnosis of minimal hepatic encephalopathy
    Weissenborn K1. J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S54-9. doi: 10.1016/j.jceh.2014.06.005. Epub 2014 Jul 31.


  113. Hepatic encephalopathy and sleepiness: an interesting connection?
    Montagnese S1, Turco M1, Amodio P1. J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S49-53. doi: 10.1016/j.jceh.2014.06.006. Epub 2014 Jun 29.


  114. Clinical neurophysiology of hepatic encephalopathy
    Amodio P1, Montagnese S1. J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S60-8. doi: 10.1016/j.jceh.2014.06.007. Epub 2014 Aug 3.


  115. Minimal hepatic encephalopathy impairs quality of life
    Agrawal S1, Umapathy S1, Dhiman RK1. J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S42-8. doi: 10.1016/j.jceh.2014.11.006. Epub 2014 Dec 4.


  116. Detecting minimal hepatic encephalopathy in an endemic country for hepatitis B: the role of psychometrics and serum IL-6
    Tsai CF1, Chu CJ2, Huang YH2, Wang YP3, Liu PY4, Lin HC2, Lee FY2, Lu CL3. PLoS One. 2015 Jun 3;10(6):e0128437. doi: 10.1371/journal.pone.0128437. eCollection 2015.


  117. Anxiety and depression symptoms in hepatic encephalopathy: are they psychiatric or organic?
    Telles-Correia D1, João Freire M2, Mega I3, Barreiras D4, Cortez Pinto H2. Transplant Proc. 2015 May;47(4):1005-7. doi: 10.1016/j.transproceed.2015.03.011.


  118. The confusion assessment method for the intensive care unit in patients with cirrhosis
    Orman ES1, Perkins A, Ghabril M, Khan BA, Chalasani N, Boustani MA. Metab Brain Dis. 2015 May 7. [Epub ahead of print]


  119. Cognitive dysfunction and hepatitis C virus infection
    Solinas A1, Piras MR1, Deplano A1. World J Hepatol. 2015 May 8;7(7):922-5. doi: 10.4254/wjh.v7.i7.922.


  120. The etiology of cirrhosis is a strong determinant of brain reserve: A multi-modal MR imaging study
    Ahluwalia V1, Wade JB, Moeller FG, White MB, Unser AB, Gavis EA, Sterling RK, Stravitz RT, Sanyal AJ, Siddiqui MS, Puri P, Luketic V, Heuman DM, Fuchs M, Matherly S, Bajaj JS. Liver Transpl


  121. Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis
    Zhang Y1, Feng Y1, Cao B2, Tian Q1. Int J Clin Exp Med. 2015 Feb 15;8(2):2954-7. eCollection 2015.


  122. Covert hepatic encephalopathy: does the mini-mental state examination help?
    Corrias M1, Turco M1, Rui MD1, Gatta A1, Angeli P1, Merkel C1, Amodio P1, Schiff S1, Montagnese S1. J Clin Exp Hepatol. 2014 Jun;4(2):89-93. doi: 10.1016/j.jceh.2013.12.005. Epub 2014 Jan 24.


  123. Presentation and complications associated with cirrhosis of the liver
    Poordad FF1. Curr Med Res Opin. 2015 May;31(5):925-37. doi: 10.1185/03007995.2015.1021905.


  124. Branched-chain amino acids for people with hepatic encephalopathy
    Gluud LL1, Dam G, Les I, Córdoba J, Marchesini G, Borre M, Aagaard NK, Vilstrup H. Cochrane Database Syst Rev. 2015 Feb 25;2:CD001939. doi: 10.1002/14651858.CD001939.pub2.


  125. Impact of Physician Specialty on Quality Care for Patients Hospitalized with Decompensated Cirrhosis
    Lim N1, Lidofsky SD1. PLoS One. 2015 Apr 2;10(4):e0123490. doi: 10.1371/journal.pone.0123490.


  126. Management of patients with decompensated cirrhosis
    Harrison PM1. Clin Med. 2015 Apr;15(2):201-3. doi: 10.7861/clinmedicine.15-2-201.


  127. Salivary Microbiota Reflects Changes in Gut Microbiota in Cirrhosis with Hepatic Encephalopathy
    Bajaj JS1, Betrapally NS, Hylemon PB, Heuman DM, Daita K, White MB, Unser A, Thacker LR, Sanyal AJ, Kang DJ, Sikaroodi M, Gillevet PM. Hepatology. 2015 Mar 29. doi: 10.1002/hep.27819. [Epub ahead of print]


  128. Psychoactive Medications Increase the Risk of Falls and Fall-Related Injuries in Hospitalized Patients with Cirrhosis
    Tapper EB1, Risech-Neyman Y2, Sengupta N3. Clin Gastroenterol Hepatol. 2015 Mar 25. pii: S1542-3565(15)00305-5. doi: 10.1016/j.cgh.2015.03.019. [Epub ahead of print]


  129. Interferon gamma, interleukin-6, and -17a levels were correlated with minimal hepatic encephalopathy in HBV patients
    Li W1, Li N, Wang R, Li Q, Wu H. Hepatol Int. 2015 Mar 21. [Epub ahead of print]


  130. Nutrition in the management of cirrhosis and its neurological complications
    Bémeur C1, Butterworth RF2. J Clin Exp Hepatol. 2014 Jun;4(2):141-50. doi: 10.1016/j.jceh.2013.05.008. Epub 2013 Jun 11.


  131. Covert hepatic encephalopathy: does the mini-mental state examination help?
    Corrias M1, Turco M1, Rui MD1, Gatta A1, Angeli P1, Merkel C1, Amodio P1, Schiff S1, Montagnese S1. J Clin Exp Hepatol. 2014 Jun;4(2):89-93. doi: 10.1016/j.jceh.2013.12.005. Epub 2014 Jan 24.


  132. Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview
    Adinolfi LE1, Nevola R1, Lus G1, Restivo L1, Guerrera B1, Romano C1, Zampino R1, Rinaldi L1, Sellitto A1, Giordano M1, Marrone A1. World J Gastroenterol. 2015 Feb 28;21(8):2269-2280.


  133. Presentation and complications associated with cirrhosis of the liver
    Poordad FF1. Curr Med Res Opin. 2015 Feb 20:1-27. [Epub ahead of print]


  134. Branched-chain amino acids for people with hepatic encephalopathy
    Gluud LL1, Dam G, Les I, Córdoba J, Marchesini G, Borre M, Aagaard NK, Vilstrup H. Cochrane Database Syst Rev. 2015 Feb 25;2:CD001939. [Epub ahead of print]


  135. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy
    Zhu GQ1, Shi KQ, Huang S, Wang LR, Lin YQ, Huang GQ, Chen YP, Braddock M, Zheng MH. Aliment Pharmacol Ther. 2015 Feb 13. doi: 10.1111/apt.13122. [Epub ahead of print]


  136. Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANONIC study
    Cárdenas A, Solà E, Rodríguez E, Barreto R, Graupera I, Pavesi M, Saliba F, Welzel T, Martinez-Gonzalez J, Gustot T, Bernardi M, Arroyo V, Ginès P; CANONIC study investigators of the EASL-CLIF Consortium. Crit Care. 2014 Dec 13;18(6):700. [Epub ahead of print]


  137. Patients with manifest hepatic encephalopathy can reveal impaired thermal perception
    Brenner M1, Butz M, May ES, Kahlbrock N, Kircheis G, Häussinger D, Schnitzler A. Acta Neurol Scand. 2015 Jan 28. doi: 10.1111/ane.12376. [Epub ahead of print]


  138. Protein restriction in hepatic encephalopathy is appropriate for selected patients: a point of view
    Nguyen DL1, Morgan T1. Hepatol Int. 2014 Sep 1;8(2):447-451.


  139. The mind and liver test: a new approach to the diagnosis of minimal hepatic encephalopathy in resource-poor settings
    Das S1, Ali SM1, Seward J2, Venkataraman J3. Int J Hepatol. 2014;2014:475021. doi: 10.1155/2014/475021. Epub 2014 Dec 8.


  140. PET and MR imaging of neuroinflammation in hepatic encephalopathy
    Su YY1, Yang GF, Lu GM, Wu S, Zhang LJ. Metab Brain Dis. 2014 Dec 17. [Epub ahead of print]


  141. Efficacy and Tolerability of Rifaximin in Combination With Lactulose in End-stage Liver Disease Patients With MELD Greater Than 20: A Single Center Experience
    Mantry PS1, Mehta A2, Graydon R2. Transplant Proc. 2014 Dec;46(10):3481-6. doi: 10.1016/j.transproceed.2014.10.021.


  142. Is There a Role for Probiotics in Liver Disease?
    Lo RS, Austin AS, Freeman JG. ScientificWorldJournal. 2014;2014:874768. Epub 2014 Nov 11.


  143. Covert hepatic encephalopathy: Agreement and predictive validity of different indices
    Montagnese S, Balistreri E, Schiff S, De Rui M, Angeli P, Zanus G, Cillo U, Bombonato G, Bolognesi M, Sacerdoti D, Gatta A, Merkel C, Amodio P. World J Gastroenterol. 2014 Nov 14;20(42):15756-62. doi: 10.3748/wjg.v20.i42.15756.


  144. Rifaximin: a review of its use in reducing recurrence of overt hepatic encephalopathy episodes
    Scott LJ. Drugs. 2014 Dec;74(18):2153-60. doi: 10.1007/s40265-014-0300-y.


  145. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis
    Bajaj JS1, Barrett AC, Bortey E, Paterson C, Forbes WP. Aliment Pharmacol Ther. 2014 Oct 22. doi: 10.1111/apt.12993. [Epub ahead of print]


  146. Rifaximin: A Review of Its Use in Reducing Recurrence of Overt Hepatic Encephalopathy Episodes
    Scott LJ. Drugs. 2014 Oct 29. [Epub ahead of print]


  147. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis
    Bajaj JS1, Barrett AC, Bortey E, Paterson C, Forbes WP. Aliment Pharmacol Ther. 2014 Oct 22. doi: 10.1111/apt.12993. [Epub ahead of print]


  148. FOUR Score, a Reliable Score for Assessing Overt Hepatic Encephalopathy in Cirrhotic Patients
    Mouri S1, Tripon S, Rudler M, Mallet M, Mayaux J, Thabut D, Weiss N. Neurocrit Care. 2014 Oct 21. [Epub ahead of print]


  149. MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy
    Martel-Laferrière V1, Homberger C, Bichoupan K, Dieterich DT. BMC Gastroenterol. 2014 Oct 17;14(1):185. doi: 10.1186/1471-230X-14-185.


  150. THDP17 Decreases Ammonia Production through Glutaminase Inhibition. A New Drug for Hepatic Encephalopathy Therapy
    Díaz-Herrero MM1, Del Campo JA2, Carbonero-Aguilar P1, Vega-Pérez JM3, Iglesias-Guerra F3, Periñán I3, Miñano FJ4, Bautista J1, Romero-Gómez M2. PLoS One. 2014 Oct 17;9(10):e109787. doi: 10.1371/journal.pone.0109787. eCollection 2014.


  151. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy- a non-inferiority randomized controlled trial
    Pratap Mouli V1, Benjamin J, Bhushan Singh M, Mani K, Garg SK, Saraya A, Joshi YK. Hepatol Res. 2014 Sep 29. doi: 10.1111/hepr.12429. [Epub ahead of print]


  152. Reestablishing brain networks in patients without overt hepatic encephalopathy after liver transplantation
    Lin WC1, Hsu TW2, Chen CL3, Lu CH4, Chen HL5, Cheng YF1, Lin CP6. J Cereb Blood Flow Metab. 2014 Sep 17. doi: 10.1038/jcbfm.2014.143. [Epub ahead of print]


  153. Management of Complications of End-Stage Liver Disease in the Intensive Care Unit
    DellaVolpe JD1, Garavaglia JM2, Huang DT3. J Intensive Care Med. 2014 Sep 15. pii: 0885066614551144. [Epub ahead of print]


  154. Ammonia and amino acid profiles in liver cirrhosis: Effects of variables leading to hepatic encephalopathy
    Holecek M. Nutrition. 2014 Mar 30. pii: S0899-9007(14)00150-6. doi: 10.1016/j.nut.2014.03.016. [Epub ahead of print]


  155. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute on chronic liver failure
    Romero-Gómez M1, Montagnese S2, Jalan R3. J Hepatol. 2014 Sep 9. pii: S0168-8278(14)00646-1. doi: 10.1016/j.jhep.2014.09.005. [Epub ahead of print]


  156. Non invasive blood flow measurement in cerebellum detects minimal hepatic encephalopathy earlier than psychometric tests
    Felipo V, Urios A, Giménez-Garzó C, Cauli O, Andrés-Costa MJ, González O, Serra MA, Sánchez-González J, Aliaga R, Giner-Durán R, Belloch V, Montoliu C. World J Gastroenterol. 2014 Sep 7;20(33):11815-25. doi: 10.3748/wjg.v20.i33.11815.


  157. Covert Hepatic Encephalopathy Is Independently Associated With Poor Survival and Increased Risk of Hospitalization
    Patidar KR1, Thacker LR2, Wade JB3, Sterling RK1, Sanyal AJ1, Siddiqui MS1, Matherly SC1, Stravitz RT1, Puri P1, Luketic VA1, Fuchs M1, White MB1, Noble NA1, Unser AB1, Gilles H1, Heuman DM1, Bajaj JS1. Am J Gastroenterol. 2014 Sep 2. doi: 10.1038/ajg.2014.264. [Epub ahead of print]


  158. Concise review of current concepts on nomenclature and pathophysiology of hepatic encephalopathy
    Savlan I1, Liakina V2, Valantinas J3. Medicina (Kaunas). 2014;50(2):75-81. doi: 10.1016/j.medici.2014.06.008. Epub 2014 Jun 27.


  159. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: A randomized controlled trial
    Sharma K1, Pant S, Misra S, Dwivedi M, Misra A, Narang S, Tewari R, Bhadoria AS. Saudi J Gastroenterol. 2014 Jul-Aug;20(4):225-32. doi: 10.4103/1319-3767.136975.


  160. Confounders in the detection of minimal hepatic encephalopathy: a neuropsychological and quantified EEG study
    Campagna F1, Montagnese S, Schiff S, Ruzzoli M, Biancardi A, Iannizzi P, Pujatti PL, Angeli P, Gatta A, Merkel C, Leandro G, Mapelli D, Amodio P. Liver Int. 2014 Jul 9. doi: 10.1111/liv.12635. [Epub ahead of print]


  161. Disrupted small world networks in patients without overt hepatic encephalopathy: A resting state fMRI study
    Zhang LJ1, Zheng G2, Zhang L3, Zhong J4, Li Q3, Zhao TZ2, Lu GM5. Eur J Radiol. 2014 Jul 2. pii: S0720-048X(14)00337-4. doi: 10.1016/j.ejrad.2014.06.019. [Epub ahead of print]


  162. Brain oscillatory activity during sleep shows unknown dysfunctions in early encephalopathy
    Martino ME1, Fernández-Lorente J, Romero-Vives M, Bárcena R, Gaztelu JM. J Physiol Biochem. 2014 Jul 30. [Epub ahead of print]


  163. Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis: an updated meta-analysis of six randomized controlled trials
    Xu J1, Ma R, Chen LF, Zhao LJ, Chen K, Zhang RB. Hepatobiliary Pancreat Dis Int. 2014 Aug;13(4):354-60.


  164. Correction of Hyponatremia Improves Cognition, Quality of Life, and Brain Edema in Cirrhosis
    Ahluwalia V1, Heuman DM2, Feldman G3, Wade JB4, Thacker LR5, Gavis E2, Gilles H2, Unser A2, White MB2, Bajaj JS6. J Hepatol. 2014 Aug 8. pii: S0168-8278(14)00537-6. doi: 10.1016/j.jhep.2014.07.033. [Epub ahead of print]


  165. Challenges in Diagnosing Hepatic Encephalopathy
    Weissenborn K. Neurochem Res. 2014 Aug 21. [Epub ahead of print]


  166. Validation of EncephalApp, Smartphone-based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy.
    Bajaj JS1, Heuman DM2, Sterling RK2, Sanyal AJ2, Siddiqui M2, Matherly S2, Luketic V2, Stravitz RT2, Fuchs M2, Thacker LR3, Gilles H2, White MB2, Unser A2, Hovermale J2, Gavis E2, Noble NA2, Wade JB4.


  167. Hepatic encephalopathy: how to test and treat
    Rahimi RS1, Rockey DC. Curr Opin Gastroenterol. 2014 May;30(3):265-71. doi: 10.1097/MOG.0000000000000066.


  168. Brain magnetic resonance in hepatic encephalopathy
    Alonso J1, Córdoba J2, Rovira A3. Semin Ultrasound CT MR. 2014 Apr;35(2):136-52. doi: 10.1053/j.sult.2013.09.008.


  169. Sodium benzoate for treatment of hepatic encephalopathy
    Misel ML, Gish RG, Patton H, Mendler M. Gastroenterol Hepatol (N Y). 2013 Apr;9(4):219-27.


  170. Survival in infection-related acute-on-chronic liver failure is defined by extra-hepatic organ failures
    Bajaj JS1, O'Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, Fallon MB, Garcia-Tsao G, Maliakkal B, Malik R, Subramanian RM, Thacker LR, Kamath PS; on behalf of NACSELD. Hepatology. 2014 Feb 20. doi: 10.1002/hep.27077. [Epub ahead of print]


  171. Cerebral Hemodynamics In Cirrhotic Patients With Hepatic Encephalopathy
    Macías-Rodríguez RU1, Duarte-Rojo A, Cantú-Brito C, Sauerbruch T, Ruiz-Margáin A, Trebicka J, Green-Gómez M, Díaz Ramírez JB, Sierra Beltrán M, Uribe-Esquivel M, Torre A. Liver Int. 2014 Apr 1. doi: 10.1111/liv.12557. [Epub ahead of print]


  172. Management of hyponatremia in clinical hepatology practice
    Kwo PY. Curr Gastroenterol Rep. 2014 May;16(5):382. doi: 10.1007/s11894-014-0382-4.


  173. Branched-chain amino acid supplementation in adults with cirrhosis and porto-systemic encephalopathy: Systematic review
    Metcalfe EL1, Avenell A2, Fraser A3. Clin Nutr. 2014 Mar 6. pii: S0261-5614(14)00073-9. doi: 10.1016/j.clnu.2014.02.011. [Epub ahead of print]


  174. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: An updated meta-analysis
    Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH. World J Gastroenterol. 2014 Mar 14;20(10):2704-2714.


  175. Optimal treatment of hepatic encephalopathy
    Waghray A1, Waghray N, Kanna S, Mullen K. Minerva Gastroenterol Dietol. 2014 Mar;60(1):55-70.


  176. Treatment Options for Covert Hepatic Encephalopathy
    Waghray N1, Waghray A, Mullen K. Curr Treat Options Gastroenterol. 2014 Mar 13. [Epub ahead of print]


  177. Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests
    Berlioux P, Robic MA, Poirson H, Métivier S, Otal P, Barret C, Lopez F, Péron JM, Vinel JP, Bureau C. Hepatology. 2014 Feb;59(2):622-9.


  178. Asterixis: a study of 103 patients
    Pal G1, Lin MM, Laureno R. Metab Brain Dis. 2014 Mar 7. [Epub ahead of print]


  179. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: Implications for the gut-liver-brain axis
    Ahluwalia V1, Wade JB, Heuman DM, Hammeke TA, Sanyal AJ, Sterling RK, Stravitz RT, Luketic V, Siddiqui MS, Puri P, Fuchs M, Lennon MJ, Kraft KA, Gilles H, White MB, Noble NA, Bajaj JS. Metab Brain Dis. 2014 Mar 4. [Epub ahead of print]


  180. Does H. pylori Eradication Therapy Benefit Patients With Hepatic Encephalopathy?: Systematic Review
    Schulz C1, Schütte K, Malfertheiner P. J Clin Gastroenterol. 2014 Feb 27. [Epub ahead of print]


  181. Direct acting inhibitors of ammoniagenesis: a role in post-TIPS encephalopathy?
    Ahuja NK, Ally WA, Caldwell SH. Ann Hepatol. 2014 Mar-Apr;13(2):179-86.


  182. Bacterial Infections in Cirrhosis. A Position Statement based on the EASL Special Conference 2013
    Jalan R1, Fernandez J2, Wiest R3, Schnabl B4, Moreau R5, Angeli P6, Stadlbauer V7, Thierry Gustot T8, Bernardi M9, Canton R10, Agustin Albillos A11, Lammert F12, Wilmer A13, Mookerjee R1, Vila J14, Garcia-Martinez R2, Wendon J15, Such J16, Cordoba J17, Sanyal A18, Garcia-Tsao G19, Arroyo V2, Burroughs A20, Ginès P21. J Hepatol. 2014 Feb 11. pii: S0168-8278(14)00097-X. doi: 10.1016/j.jhep.2014.01.024. [Epub ahead of print]


  183. Analgesia for the Cirrhotic Patient: A Literature Review and Recommendations
    Dwyer JP1, Jayasekera C, Nicoll A. J Gastroenterol Hepatol. 2014 Feb 18. doi: 10.1111/jgh.12560. [Epub ahead of print]


  184. Effects of hyperammonemia on brain energy metabolism: controversial findings in vivo and in vitro
    Schousboe A1, Waagepetersen HS, Leke R, Bak LK. Metab Brain Dis. 2014 Mar 1. [Epub ahead of print]


  185. Rifaximin is Safe and Well Tolerated for Long-Term Maintenance of Remission From Overt Hepatic Encephalopathy
    Mullen KD1, Sanyal AJ2, Bass NM3, Poordad FF4, Sheikh MY5, Frederick RT6, Bortey E7, Forbes WP7. Clin Gastroenterol Hepatol. 2013 Dec 21. pii: S1542-3565(13)01968-X. doi: 10.1016/j.cgh.2013.12.021. [Epub ahead of print]


  186. Role of Magnetic Resonance Elastography in compensated and decompensated liver disease
    Asrani SK1, Talwalkar JA2, Kamath PS3, Shah VH4, Saracino G5, Jennings L6, Gross JB7, Venkatesh S8, Ehman RL9. J Hepatol. 2013 Dec 19. pii: S0168-8278(13)00884-2. doi: 10.1016/j.jhep.2013.12.016. [Epub ahead of print]


  187. The Cirrhosis Dysbiosis Ratio defines Changes in the Gut Microbiome Associated with Cirrhosis and its Complications
    Bajaj JS1, Heuman DM2, Hylemon PB3, Sanyal AJ2, White MB2, Monteith P2, Noble NA2, Unser AB2, Daita K3, Fisher AR4, Sikaroodi M4, Gillevet PM4. J Hepatol. 2013 Dec 24. pii: S0168-8278(13)00887-8. doi: 10.1016/j.jhep.2013.12.019. [Epub ahead of print]


  188. Diagnosis of Covert Hepatic Encephalopathy Without Specialized Tests
    Nabi E1, Thacker LR2, Wade JB3, Sterling RK1, Stravitz RT1, Fuchs M1, Heuman DM1, Bouneva I1, Sanyal AJ1, Siddiqui MS1, Luketic V1, White MB1, Monteith P1, Noble NA1, Unser A1, Bajaj JS4. Clin Gastroenterol Hepatol. 2013 Dec 19. pii: S1542-3565(13)01966-6. doi: 10.1016/j.cgh.2013.12.020. [Epub ahead of print]


  189. Useful tests for hepatic encephalopathy in clinical practice
    Nabi E, Bajaj JS. Curr Gastroenterol Rep. 2014 Jan;16(1):362. doi: 10.1007/s11894-013-0362-0.


  190. Microglial proliferation in the brain of chronic alcoholics with hepatic encephalopathy
    Dennis CV, Sheahan PJ, Graeber MB, Sheedy DL, Kril JJ, Sutherland GT. Metab Brain Dis. 2013 Dec 19. [Epub ahead of print]


  191. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)
    Poynard T1, Vergniol J2, Ngo Y3, Foucher J2, Munteanu M3, Merrouche W2, Colombo M4, Thibault V5, Schiff E6, Brass CA7, Albrecht JK7, Rudler M8, Deckmyn O3, Lebray P8, Thabut D8, Ratziu V8, de Ledinghen V2; FibroFrance Study Group; Epic3 Study Group; Bordeaux HCV Study Group. J Hepatol. 2013 Nov 26. pii: S0168-8278(13)00817-9. doi: 10.1016/j.jhep.2013.11.016. [Epub ahead of print]


  192. Management of End-stage Liver Disease
    Liou IW. Med Clin North Am. 2014 Jan;98(1):119-52. doi: 10.1016/j.mcna.2013.09.006. Epub 2013 Oct 30.


  193. Branched-chain amino acids in liver diseases
    Tajiri K, Shimizu Y. World J Gastroenterol. 2013 Nov 21;19(43):7620-9. doi: 10.3748/wjg.v19.i43.7620.


  194. Treatment of hyperammonemia in liver failure
    Jover-Cobos M, Khetan V, Jalan R. Curr Opin Clin Nutr Metab Care. 2014 Jan;17(1):105-10. doi: 10.1097/MCO.0000000000000012.


  195. Impact of Pretransplant Hepatic Encephalopathy on Liver Posttransplantation Outcomes
    Teperman LW. Int J Hepatol. 2013;2013:952828. Epub 2013 Nov13.


  196. Increased toll-like receptor 4 in cerebral endothelial cells contributes to the astrocyte swelling and brain edema in acute hepatic encephalopathy
    Jayakumar AR, Tong XY, Curtis KM, Ruiz-Cordero R, Abreu MT, Norenberg MD. J Neurochem. 2013 Nov 1. doi: 10.1111/jnc.12516. [Epub ahead of print]


  197. Probiotics Prevent Hepatic Encephalopathy in Patients with Cirrhosis: a Randomized Controlled Trial
    Lunia MK, Chander Sharma B, Sharma P, Sachdeva S, Srivastava S. Clin Gastroenterol Hepatol. 2013 Nov 15. pii: S1542-3565(13)01743-6. doi: 10.1016/j.cgh.2013.11.006. [Epub ahead of print]


  198. Recent insights into the pathogenesis of hepatic encephalopathy and treatments
    Sturgeon JP, Shawcross DL. Expert Rev Gastroenterol Hepatol. 2013 Nov 18. [Epub ahead of print]


  199. Diffusion-weighted imaging in acute hyperammonemic encephalopathy
    Rosario M, McMahon K, Finelli PF. Neurohospitalist. 2013 Jul;3(3):125-30. doi: 10.1177/1941874412467806.


  200. Persistent repeated measurements by Magnetic Resonance Spectroscopy demonstrate Minimal Hepatic Encephalopathy: a case report
    Scheau C, Popa G, Ghergus A, Preda E, Capsa R, Lupescu I. J Med Life. 2013 Sep 15;6(3):299-301. Epub 2013 Sep 25.


  201. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio
    Mokhtarani M, Diaz GA, Rhead W, Berry SA, Lichter-Konecki U, Feigenbaum A, Schulze A, Longo N, Bartley J, Berquist W, Gallagher R, Smith W, McCandless SE, Harding C, Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS Jr, Dickinson K, Moors T, Norris C, Coakley D, Milikien DA, Nagamani SC, Lemons C, Lee B, Scharschmidt BF. Mol Genet Metab. 2013 Oct 8. pii: S1096-7192(13)00329-6. doi: 10.1016/j.ymgme.2013.09.017. [Epub ahead of print]


  202. A study on the position and etiology of infection in cirrhotic patients: A potential precipitating factor contributing to hepatic encephalopathy
    Wang QM, Ji Q, Duan ZJ, Zhang M, Chang QY.


  203. Hepatic encephalopathy: effects of liver failure on brain function
    Felipo V. Nat Rev Neurosci. 2013 Oct 23. doi: 10.1038/nrn3587. [Epub ahead of print]


  204. Oral glutamine challenge improves the performance of psychometric tests for the diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis
    Irimia R, Stanciu C, Cojocariu C, Sfarti C, Trifan A. J Gastrointestin Liver Dis. 2013 Sep;22(3):277-81.


  205. Pathophysiology of Encephalopathy and Delirium
    Williams ST. J Clin Neurophysiol. 2013 Oct;30(5):435-437.


  206. Insight into the relationship between brain/behavioral speed and variability in patients with minimal hepatic encephalopathy
    Schiff S, D'Avanzo C, Cona G, Goljahani A, Montagnese S, Volpato C, Gatta A, Sparacino G, Amodio P, Bisiacchi P. Clin Neurophysiol. 2013 Sep 10. pii: S1388-2457(13)00983-8. doi: 10.1016/j.clinph.2013.08.004. [Epub ahead of print]


  207. Clinical and radiological impact of liver transplantation for brain in cirrhosis patients without hepatic encephalopathy
    Ishihara T, Ito M, Niimi Y, Tsujimoto M, Senda J, Kawai Y, Watanabe H, Ishigami M, Ito T, Kamei H, Onishi Y, Nakamura T, Goto H, Naganawa S, Kiuchi T, Sobue G. Clin Neurol Neurosurg. 2013 Sep 10. pii: S0303-8467(13)00318-1. doi: 10.1016/j.clineuro.2013.08.015. [Epub ahead of print]


  208. Roles of Changes in Active Glutamine Transport in Brain Edema Development During Hepatic Encephalopathy: An Emerging Concept
    Zielinska M, Popek M, Albrecht J. Neurochem Res. 2013 Sep 26. [Epub ahead of print]


  209. Prevalence of Minimal Hepatic Encephalopathy and Quality of Life in Patients with Decompensated Cirrhosis
    Mina A, Moran S, Ortiz-Olvera N, Mera R, Uribe M. Hepatol Res. 2013 Aug 19. doi: 10.1111/hepr.12227. [Epub ahead of print]


  210. Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: a randomized, double blind placebo-controlled trial
    Alvares-da-Silva MR, de Araujo A, Vicenzi JR, da Silva GV, Oliveira FB, Schacher F, Oliboni L, Magnus A, Kruel LP, Prieb R, Fernandes LN. Hepatol Res. 2013 Sep 3. doi: 10.1111/hepr.12235. [Epub ahead of print]


  211. In patients with liver cirrhosis, proinflammatory interleukins correlate with health-related quality of life irrespective of minimal hepatic encephalopathy
    Wunsch E, Koziarska D, Milkiewicz M, Naprawa G, Nowacki P, Hartleb M, Milkiewicz P. Eur J Gastroenterol Hepatol. 2013 Sep 9. [Epub ahead of print]


  212. Image-guided Intervention in Management of Complications of Portal Hypertension: More than TIPS for Success
    Kirby JM, Cho KJ, Midia M. Radiographics. 2013 Sep;33(5):1473-96. doi: 10.1148/rg.335125166.


  213. Oral Acetyl-L-Carnitine treatment in hepatic encephalopathy: view of evidence-based medicine
    Jiang Q, Jiang G, Shi KQ, Cai H, Wang YX, Zheng MH. Ann Hepatol. 2013 Sep-Oct;12(5):803-9.


  214. Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives
    Holecek M. Metab Brain Dis. 2013 Aug 31. [Epub ahead of print]


  215. Evolving Concepts: The Negative Effect of Minimal Hepatic Encephalopathy and Role for Prophylaxis in Patients With Cirrhosis
    Prakash RK, Kanna S, Mullen KD. Clin Ther. 2013 Aug 22. pii: S0149-2918(13)00811-4. doi: 10.1016/j.clinthera.2013.07.421. [Epub ahead of print]


  216. Update on management of patients with overt hepatic encephalopathy
    Chacko KR, Sigal SH. Hosp Pract (1995). 2013 Aug;41(3):48-59. doi: 10.3810/hp.2013.08.1068.


  217. The thalamus in cirrhotic patients with and without hepatic encephalopathy: A volumetric MRI study
    Tao R, Zhang J, You Z, Wei L, Fan Y, Cui J, Wang J. Eur J Radiol. 2013 Aug 15. pii: S0720-048X(13)00404-X. doi: 10.1016/j.ejrad.2013.07.029. [Epub ahead of print]


  218. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China
    Wang JY, Zhang NP, Chi BR, Mi YQ, Meng LN, Liu YD, Wang JB, Jiang HX, Yang JH, Xu Y, Li X, Xu JM, Zhang G, Zhou XM, Zhuge YZ, Tian DA, Ye J, Liu YL. World J Gastroenterol. 2013 Aug 14;19(30):4984-91. doi: 10.3748/wjg.v19.i30.4984.


  219. Effects of Oral Branched-Chain Amino Acids on Hepatic Encephalopathy and Outcome in Patients With Liver Cirrhosis
    Kawaguchi T, Taniguchi E, Sata M. Nutr Clin Pract. 2013 Aug 14. [Epub ahead of print]


  220. Rifaximin-mediated changes to the epithelial cell proteome: 2-d gel analysis
    Schrodt C, McHugh EE, Gawinowicz MA, Dupont HL, Brown EL. PLoS One. 2013 Jul 26;8(7):e68550. doi: 10.1371/journal.pone.0068550. Print 2013.


  221. Rehabilitation for cirrhotic patients discharged after hepatic encephalopathy improves survival
    Andersen MM, Aunt S, Jensen NM, Homann C, Manniche J, Svendsen S, Christensen E, Reher-Langberg A, Schiødt FV. Dan Med J. 2013 Aug;60(8):A4683.


  222. Contributions of microdialysis to new alternative therapeutics for hepatic encephalopathy
    Rivera-Espinosa L, Floriano-Sánchez E, Pedraza-Chaverrí J, Coballase-Urrutia E, Sampieri AI, Ortega-Cuellar D, Cárdenas-Rodríguez N, Carmona-Aparicio L. Int J Mol Sci. 2013 Aug 5;14(8):16184-206. doi: 10.3390/ijms140816184.


  223. A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy
    Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. Am J Gastroenterol. 2013 Jul 23. doi: 10.1038/ajg.2013.219. [Epub ahead of print]


  224. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: A randomized double-blind study
    Simón-Talero M, García-Martínez R, Torrens M, Augustin S, Gómez S, Pereira G, Guevara M, Ginés P, Soriano G, Román E, Sánchez-Delgado J, Ferrer R, Nieto JC, Sunyé P, Fuentes I, Esteban R, Córdoba J. J Hepatol. 2013 Jul 18. pii: S0168-8278(13)00531-X. doi: 10.1016/j.jhep.2013.07.020. [Epub ahead of print]


  225. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy
    Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS Jr, Alexeeva O, Zupanets IA, Grinevich V, Baranovsky A, Dudar L, Fadieienko G, Kharchenko N, Klaryts'ka I, Morozov V, Grewal P, McCashland T, Reddy KG, Reddy KR, Syplyviy V, Bass NM, Dickinson K, Norris C, Coakley D, Mokhtarani M, Scharschmidt BF; HALT-HE Study Group. Hepatology. 2013 Jul 11. doi: 10.1002/hep.26611. [Epub ahead of print]


  226. Cerebral blood flow measured by arterial-spin labeling MRI: A useful biomarker for characterization of minimal hepatic encephalopathy in patients with cirrhosis
    Zheng G, Zhang LJ, Zhong J, Wang Z, Qi R, Shi D, Lu GM. Eur J Radiol. 2013 Jul 9. pii: S0720-048X(13)00295-7. doi: 10.1016/j.ejrad.2013.06.002. [Epub ahead of print]


  227. Cerebral oedema is rare in acute-on-chronic liver failure patients presenting with high-grade hepatic encephalopathy
    Joshi D, O'Grady J, Patel A, Shawcross D, Connor S, Deasy N, Willars C, Bernal W, Wendon J, Auzinger G. Liver Int. 2013 Jun 20. doi: 10.1111/liv.12257. [Epub ahead of print]


  228. Grey and white matter abnormalities in minimal hepatic encephalopathy: a study combining voxel-based morphometry and tract-based spatial statistics
    Qi R, Zhang LJ, Zhong J, Zhu T, Zhang Z, Xu C, Zheng G, Lu GM. Eur Radiol. 2013 Jul 10. [Epub ahead of print]


  229. Association of Helicobacter pylori infection with hepatic encephalopathy risk: A systematic review
    Hu BL, Wang HY, Yang GY. Clin Res Hepatol Gastroenterol. 2013 Jul 2. pii: S2210-7401(13)00116-2. doi: 10.1016/j.clinre.2013.05.004. [Epub ahead of print]


  230. Abnormal baseline brain activity in patients with HBV-related cirrhosis without overt hepatic encephalopathy revealed by resting-state functional MRI
    Lv XF, Ye M, Han LJ, Zhang XL, Cai PQ, Jiang GH, Qiu YW, Qiu SJ, Wu YP, Liu K, Liu ZY, Wu PH, Xie CM. Metab Brain Dis. 2013 Jul 9. [Epub ahead of print]


  231. Mini-Mental State Examination in patients with hepatic encephalopathy and liver cirrhosis: a prospective, quantified electroencephalography study
    Koziarska D, Wunsch E, Milkiewicz M, Wójcicki M, Nowacki P, Milkiewicz P. BMC Gastroenterol. 2013 Jul 2;13:107. doi: 10.1186/1471-230X-13-107.


  232. The liver-brain axis in liver failure: neuroinflammation and encephalopathy
    Butterworth RF. Nat Rev Gastroenterol Hepatol. 2013 Jul 2. doi: 10.1038/nrgastro.2013.99. [Epub ahead of print]


  233. Therapeutic effects of blood purification in treatment of fulminant hepatic failure
    Pu Y, Yang D, Mao Y, Zhang Y, Chen K. Braz J Infect Dis. 2013 Jun 26. pii: S1413-8670(13)00100-1. doi: 10.1016/j.bjid.2012.11.008. [Epub ahead of print]


  234. Feasibility of adjunct therapeutic hypothermia treatment for hyperammonemia and encephalopathy due to urea cycle disorders and organic acidemias
    Lichter-Konecki U, Nadkarni V, Moudgil A, Cook N, Poeschl J, Meyer MT, Dimmock D, Baumgart S. Mol Genet Metab. 2013 May 29. pii: S1096-7192(13)00180-7. doi: 10.1016/j.ymgme.2013.05.014. [Epub ahead of print]


  235. Acute Fulminant Hepatic Failure, Encephalopathy and Early CT Changes
    Thayapararajah SW, Gulka I, Al-Amri A, Das S, Young GB. Can J Neurol Sci. 2013 Jul;40(4):553-7.


  236. Synbiotic formulation of probiotic and lactulose combination for hepatic encephalopathy treatment: A realistic hope?
    Sekhar MS, Unnikrishnan MK, Rodrigues GS, Mukhopadhyay C. Med Hypotheses. 2013 Jun 8. pii: S0306-9877(13)00245-4. doi: 10.1016/j.mehy.2013.05.016. [Epub ahead of print]


  237. Plasmapheresis as adjuvant therapy in Stevens-Johnson syndrome and hepatic encephalopathy
    Hung PC, Wang HS, Hsia SH, Wong AM. Brain Dev. 2013 Jun 15. pii: S0387-7604(13)00174-5. doi: 10.1016/j.braindev.2013.05.010. [Epub ahead of print]


  238. Percutaneous Transvenous Embolization for Portal-Systemic Shunts associated with Encephalopathy: Long-term outcomes in 14 patients
    Naeshiro N, Kakizawa H, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Honda Y, Miyaki D, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Ishikawa M, Awai K, Chayama K. Hepatol Res. 2013 Jun 7. doi: 10.1111/hepr.12181. [Epub ahead of print]


  239. Safety of Ornithine Phenylacetate in Cirrhotic Decompensated Patients: An Open-label, Dose-escalating, Single-cohort Study
    Ventura-Cots M, Arranz JA, Simón-Talero M, Torrens M, Blanco A, Riudor E, Fuentes I, Suñé P, Soriano G, Córdoba J. J Clin Gastroenterol. 2013 Jun 6. [Epub ahead of print]


  240. Branched-chain amino acids and ammonia metabolism in liver disease: Therapeutic implications
    Holecek M. Nutrition. 2013 Jun 4. pii: S0899-9007(13)00090-7. doi: 10.1016/j.nut.2013.01.022. [Epub ahead of print]


  241. Sleep-wake abnormalities in patients with cirrhosis
    Montagnese S, De Pittà C, De Rui M, Corrias M, Turco M, Merkel C, Amodio P, Costa R, Skene DJ, Gatta A. Hepatology. 2013 Jun 6. doi: 10.1002/hep.26555. [Epub ahead of print]


  242. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy
    Chavez-Tapia NC, Cesar-Arce A, Barrientos-Gutiérrez T, Villegas-López FA, Méndez-Sanchez N, Uribe M. Nutr J. 2013 Jun 6;12(1):74. [Epub ahead of print]


  243. Oral Branched-Chain Amino Acids Have a Beneficial Effect on Manifestations of Hepatic Encephalopathy in a Systematic Review with Meta-Analyses of Randomized Controlled Trials
    Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, Risum N, Vilstrup H. J Nutr. 2013 Jun 5. [Epub ahead of print]


  244. Precipitants of hepatic encephalopathy induce rapid astrocyte swelling in an oxidative stress dependent manner
    Lachmann V, Görg B, Bidmon HJ, Keitel V, Häussinger D. Arch Biochem Biophys. 2013 May 24. pii: S0003-9861(13)00155-0. doi: 10.1016/j.abb.2013.05.004. [Epub ahead of print]


  245. Serum nitrotyrosine and psychometric tests as indicators of impaired fitness to drive in cirrhotic patients with minimal hepatic encephalopathy
    Felipo V, Urios A, Valero P, Sánchez M, Serra MA, Pareja I, Rodríguez F, Gimenez-Garzó C, Sanmartín J, Montoliu C. Liver Int. 2013 May 9. doi: 10.1111/liv.12206. [Epub ahead of print]


  246. Cognitive Dysfunction is Associated with Poor Socio-Economic Status in Patients with Cirrhosis: an International Multi-Center Study
    Bajaj JS, Riggio O, Allampati S, Prakash R, Gioia S, Onori E, Piazza N, Noble NA, White MB, Mullen KD. Clin Gastroenterol Hepatol. 2013 May 21. pii: S1542-3565(13)00689-7. doi: 10.1016/j.cgh.2013.05.010. [Epub ahead of print]


  247. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis
    Irimia R, Trifan A. Rev Med Chir Soc Med Nat Iasi. 2012 Oct-Dec;116(4):1021-7.


  248. Hepatic encephalopathy: etiology, pathogenesis, and clinical signs
    Salgado M, Cortes Y. Compend Contin Educ Vet. 2013;35(6):E1-9.


  249. Hepatic encephalopathy: diagnosis and treatment
    Salgado M, Cortes Y. Compend Contin Educ Vet. 2013;35(6):E1-E10.


  250. Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis.
    Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY. Gastroenterol Res Pract. 2013;2013:236963. doi: 10.1155/2013/236963. Epub 2013 Apr 3.


  251. Role of the heme oxygenase/carbon monoxide pathway in the pathogenesis and prevention of hepatic encephalopathy
    Wang QM, Yin XY, Duan ZJ, Guo SB, Sun XY. Mol Med Rep. 2013 May 13. doi: 10.3892/mmr.2013.1472. [Epub ahead of print]


  252. Differential Impact of Hyponatremia and Hepatic Encephalopathy on Health-Related Quality of Life and Brain Metabolite Abnormalities in Cirrhosis
    Ahluwalia V, Wade JB, Thacker L, Kraft KA, Sterling RK, Stravitz RT, Fuchs M, Bouneva I, Puri P, Luketic V, Sanyal AJ, Gilles H, Heuman DM, Bajaj JS. J Hepatol. 2013 May 7. pii: S0168-8278(13)00278-X. doi: 10.1016/j.jhep.2013.04.023. [Epub ahead of print]


  253. Update on the management of cirrhosis - focus on cost-effective preventative strategies
    Neff GW, Kemmer N, Duncan C, Alsina A. Clinicoecon Outcomes Res. 2013 Apr 12;5:143-52. doi: 10.2147/CEOR.S30675. Print 2013.


  254. Use of ImPACT to Diagnose Minimal Hepatic Encephalopathy: An Accurate, Practical, User-Friendly Internet-Based Neuropsychological Test Battery
    Tsushima M, Tsushima W, Tsushima V, Lim N, Madrigal E, Jackson C, Mendler MH. Dig Dis Sci. 2013 Apr 27. [Epub ahead of print]


  255. Cognitive assessment of patients with minimal hepatic encephalopathy in Brazil
    Torres DS, Abrantes J, Brandão-Mello CE. Metab Brain Dis. 2013 Apr 28. [Epub ahead of print]


  256. Clinical impact of arterial ammonia levels in ICU patients with different liver diseases
    Drolz A, Jäger B, Wewalka M, Saxa R, Horvatits T, Roedl K, Perkmann T, Zauner C, Kramer L, Ferenci P, Fuhrmann V. Intensive Care Med. 2013 May 1. [Epub ahead of print]


  257. Correlation between serum magnesium levels and hepatic encephalopathy in immediate post liver transplantation period
    Lopes PJ, Mei MF, Guardia AC, Stucchi RS, Udo EY, Warwar MI, Boin IF. Transplant Proc. 2013 Apr;45(3):1122-5. doi: 10.1016/j.transproceed.2013.02.011.


  258. Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: evaluation by near infrared spectroscopy
    Nakanishi H, Kurosaki M, Nakanishi K, Tsuchiya K, Noda T, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Itakura J, Anami K, Asahina Y, Enomoto N, Higuchi T, Izumi N. Hepatol Res. 2013 Apr 5. doi: 10.1111/hepr.12127. [Epub ahead of print]


  259. GABAergic transmission in hepatic encephalopathy
    Sergeeva OA. Arch Biochem Biophys. 2013 Apr 23. pii: S0003-9861(13)00118-5. doi: 10.1016/j.abb.2013.04.005. [Epub ahead of print]


  260. Inflammation and Hepatic Encephalopathy
    Coltart I, Tranah TH, Shawcross DL. Arch Biochem Biophys. 2013 Apr 10. pii: S0003-9861(13)00105-7. doi: 10.1016/j.abb.2013.03.016. [Epub ahead of print]


  261. Cognitive functions in patients with liver cirrhosis: A tendency to commit more memory errors
    Cie?ko-Michalska I, Wójcik J, Senderecka M, Wyczesany M, Binder M, Szewczyk J, Dziedzic T, S?owik A, Mach T. Med Sci Monit. 2013 Apr 19;19:283-288.


  262. Correlation between degree and quality of sleep disturbance and the level of neuropsychiatric impairment in patients with liver cirrhosis
    Samanta J, Dhiman RK, Khatri A, Thumburu KK, Grover S, Duseja A, Chawla Y. Metab Brain Dis. 2013 Mar 15. [Epub ahead of print]


  263. Increased risk of cognitive impairment in cirrhotic patients with bacterial infections
    Merli M, Lucidi C, Pentassuglio I, Giannelli V, Giusto M, Gregorio VD, Pasquale C, Nardelli S, Lattanzi B, Venditti M, Riggio O. J Hepatol. 2013 Mar 21. pii: S0168-8278(13)00190-6. doi: 10.1016/j.jhep.2013.03.012. [Epub ahead of print]


  264. Hepatic encephalopathy associated with cancer or anticancer therapy
    Willson KJ, Nott LM, Broadbridge VT, Price T. Gastrointest Cancer Res. 2013 Jan;6(1):11-6.


  265. Update on cerebral uptake of blood ammonia
    Sørensen M. Metab Brain Dis. 2013 Mar 13. [Epub ahead of print]


  266. Altered Mental Status in Cirrhosis: Etiologies and Outcomes
    Rahimi RS, Elliott AC, Rockey DC. J Investig Med. 2013 Mar 7. [Epub ahead of print]


  267. Gut microbiota and hepatic encephalopathy
    Dhiman RK. Metab Brain Dis. 2013 Mar 6. [Epub ahead of print]


  268. Lactulose Is Highly Potential in Prophylaxis of Hepatic Encephalopathy in Patients with Cirrhosis and Upper Gastrointestinal Bleeding: Results of a Controlled Randomized Trial
    Wen J, Liu Q, Song J, Tong M, Peng L, Liang H. Digestion. 2013 Mar 6;87(2):132-138. [Epub ahead of print]


  269. Neurotransmitter receptor alterations in hepatic encephalopathy: A review
    Palomero-Gallagher N, Zilles K. Arch Biochem Biophys. 2013 Mar 1. pii: S0003-9861(13)00061-1. doi: 10.1016/j.abb.2013.02.010. [Epub ahead of print]


  270. End-stage liver disease complications
    Rahimi RS, Rockey DC. Curr Opin Gastroenterol. 2013 Feb 19. [Epub ahead of print]


  271. The effect of infections on the mortality of cirrhotic patients with hepatic encephalopathy
    Hung TH, Lay CJ, Chang CM, Tsai JJ, Tsai CC, Tsai CC. Epidemiol Infect. 2013 Feb 22:1-8. [Epub ahead of print]


  272. Effect of obstructive sleep apnea on the sleep architecture in cirrhosis
    Kappus MR, Leszczyszyn DJ, Moses L, Raman S, Heuman DM, Bajaj JS. J Clin Sleep Med. 2013 Mar 15;9(3):247-51. doi: 10.5664/jcsm.2488.


  273. Gastric Varices and Hepatic Encephalopathy: Treatment with Vascular Plug and Gelatin Sponge-assisted Retrograde Transvenous Obliteration--A Primary Report
    Gwon DI, Ko GY, Yoon HK, Sung KB, Kim JH, Shin JH, Ko HK, Song HY. Radiology. 2013 Mar 12. [Epub ahead of print]


  274. L-ornithine-L-aspartate for Hepatic Encephalopathy in Patients with Cirrhosis: A Meta-analysis of Randomized Controlled Trials
    Bai M, Yang Z, Qi X, Fan D, Han G. J Gastroenterol Hepatol. 2013 Feb 21. doi: 10.1111/jgh.12142. [Epub ahead of print]


  275. Serum Endotoxin, Inflammatory mediators and Magnetic Resonance Spectroscopy before and after treatment in patients with Minimal Hepatic Encephalopathy
    Jain L, Sharma BC, Srivastava S, Puri SK, Sharma P, Sarin S. J Gastroenterol Hepatol. 2013 Feb 21. doi: 10.1111/jgh.12160. [Epub ahead of print]


  276. Modulation of neural activation following treatment of hepatic encephalopathy
    McPhail MJ, Leech R, Grover VP, Fitzpatrick JA, Dhanjal NS, Crossey MM, Pflugrad H, Saxby BK, Wesnes K, Dresner MA, Waldman AD, Thomas HC, Taylor-Robinson SD. Neurology. 2013 Feb 20. [Epub ahead of print]


  277. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy : A multi-center survey on safety & efficacy
    Laleman W, Simon-Talero M, Maleux G, Perez M, Ameloot K, Soriano G, Villalba J, Garcia-Pagan JC, Barrufet M, Jalan R, Brookes J, Thalassinos E, Burroughs AK, Cordoba J, Nevens F; on behalf of the EASL-CLIF-consortium. Hepatology. 2013 Feb 7. doi: 10.1002/hep.26314. [Epub ahead of print]


  278. The stroop smartphone APP is a short and valid method toscreen for minimal hepatic encephalopathy
    Bajaj JS, Thacker LR, Heuman DM, Fuchs M, Sterling RK, Sanyal AJ, Puri P, Siddiqui MS, Stravitz RT, Bouneva I, Luketic V, Noble N, White MB, Monteith P, Unser A, Wade JB. Hepatology. 2013 Feb 6. doi: 10.1002/hep.26309. [Epub ahead of print]


  279. Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?
    Brandi G, de Rosa F, Calzà L, Girolamo SD, Tufoni M, Ricci CS, Cirignotta F, Caraceni P, Biasco G. Liver Int. 2013 Mar;33(3):488-93. doi: 10.1111/liv.12102.


  280. Antibiotics for the treatment of hepatic encephalopathy
    Patidar KR, Bajaj JS. Metab Brain Dis. 2013 Feb 8. [Epub ahead of print]


  281. Acetyl-L-carnitine in hepatic encephalopathy
    Malaguarnera M. Metab Brain Dis. 2013 Feb 8. [Epub ahead of print]


  282. Role of branched chain amino acids in cerebral ammonia homeostasis related to hepatic encephalopathy
    Bak LK, Waagepetersen HS, Sørensen M, Ott P, Vilstrup H, Keiding S, Schousboe A. Metab Brain Dis. 2013 Jan 31. [Epub ahead of print]


  283. Altered effective connectivity network of the Basal Ganglia in low-grade hepatic encephalopathy: a resting-state FMRI study with granger causality analysis
    Qi R, Zhang LJ, Zhong J, Zhang Z, Ni L, Jiao Q, Liao W, Zheng G, Lu G. PLoS One. 2013;8(1):e53677. doi: 10.1371/journal.pone.0053677. Epub 2013 Jan 11


  284. Melatonin levels in serum and ascitic fluid of patients with hepatic encephalopathy
    Chojnacki C, Romanowski M, Winczyk K, B?asiak J, Chojnacki J. Gastroenterol Res Pract. 2012;2012:510764. doi: 10.1155/2012/510764. Epub 2012 Dec 30.


  285. Gene expression profiling in the cerebral cortex of patients with cirrhosis with and without hepatic encephalopathy
    Görg B, Bidmon HJ, Häussinger D. Hepatology. 2013 Jan 16. doi: 10.1002/hep.26265. [Epub ahead of print]


  286. Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study
    Romeiro FG, da Silva Yamashiro F, Américo MF, Corá LA, Silva GF, Miranda J, Caramori CA. BMC Gastroenterol. 2013 Jan 16;13:13. doi: 10.1186/1471-230X-13-13.


  287. Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy
    Cicho?-Lach H, Michalak A. World J Gastroenterol. 2013 Jan 7;19(1):26-34. doi: 10.3748/wjg.v19.i1.26.


  288. Lack of Clostridium difficile Infection in Patients Treated With Rifaximin for Hepatic Encephalopathy: A Retrospective Analysis
    Neff GW, Jones M, Jonas M, Ravinuthala R, Novick D, Kaiser TE, Kemmer N. J Clin Gastroenterol. 2013 Feb;47(2):188-92. doi: 10.1097/MCG.0b013e318276be13.


  289. Pathogenesis of hepatic encephalopathy
    Cie?ko-Michalska I, Szczepanek M, S?owik A, Mach T. Gastroenterol Res Pract. 2012;2012:642108. doi: 10.1155/2012/642108. Epub 2012 Dec 17.


  290. Disrupted Functional Connectivity of the Anterior Cingulate Cortex in Cirrhotic Patients without Overt Hepatic Encephalopathy: A Resting State fMRI Study
    Zhang LJ, Qi R, Zhong J, Ni L, Zheng G, Xu J, Lu GM. PLoS One. 2013;8(1):e53206. doi: 10.1371/journal.pone.0053206. Epub 2013 Jan 7.


  291. Clinical Manifestations and Treatment Options in Patients with Cirrhosis and Diabetes Mellitus
    Gundling F, Seidl H, Strassen I, Haller B, Siegmund T, Umgelter A, Pehl C, Schepp W, Schumm-Draeger PM. Digestion. 2013 Jan 10;87(2):75-84. [Epub ahead of print]


  292. The continuous reaction times method for diagnosing, grading, and monitoring minimal/covert hepatic encephalopathy.
    Metab Brain Dis. 2013 Jan 10. [Epub ahead of print] Lauridsen MM, Thiele M, Kimer N, Vilstrup H.


  293. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
    Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, Vilstrup H. Metab Brain Dis. 2012 Dec 29. [Epub ahead of print]


  294. Glutamine in the Pathogenesis of Hepatic Encephalopathy: The Trojan Horse Hypothesis Revisited
    Rama Rao KV, Norenberg MD. Neurochem Res. 2013 Jan 1. [Epub ahead of print]


  295. Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates
    Goldbecker A, Weissenborn K, Hamidi Shahrezaei G, Afshar K, Rümke S, Barg-Hock H, Strassburg CP, Hecker H, Tryc AB. Gut. 2013 Jan 7. [Epub ahead of print]


  296. Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients
    Nardelli S, Pentassuglio I, Pasquale C, Ridola L, Moscucci F, Merli M, Mina C, Marianetti M, Fratino M, Izzo C, Merkel C, Riggio O. Metab Brain Dis. 2013 Jan 8. [Epub ahead of print]


  297. How to diagnose hepatic encephalopathy in the emergency department
    Gundling F, Zelihic E, Seidl H, Haller B, Umgelter A, Schepp W, Dodt C. Ann Hepatol. 2013 Jan;12(1):108-14.


  298. Meta-analysis: the diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy
    Torlot FJ, McPhail MJ, Taylor-Robinson SD. Aliment Pharmacol Ther. 2013 Jan 7. doi: 10.1111/apt.12199. [Epub ahead of print]


  299. Resting State Cortical Electroencephalographic Rhythms in Covert Hepatic Encephalopathy and Alzheimer's Disease
    Babiloni C, Vecchio F, Del Percio C, Montagnese S, Schiff S, Lizio R, Chini G, Serviddio G, Marzano N, Soricelli A, Frisoni GB, Rossini PM, Amodio P. J Alzheimers Dis. 2012 Dec 27. [Epub ahead of print]


  300. Increased Incidence of Orthopedic Fractures in Cirrhotic Patients: A Nationwide Population-Based Study
    Tsai CF, Liu CJ, Chen TJ, Chu CJ, Lin HC, Lee FY, Su TP, Lu CL. J Hepatol. 2012 Dec 10. pii: S0168-8278(12)00919-1. doi: 10.1016/j.jhep.2012.12.001. [Epub ahead of print]


  301. Prevention and treatment of hepatic encephalopathy: Focusing on gut microbiota
    Garcovich M, Zocco MA, Roccarina D, Ponziani FR, Gasbarrini A. World J Gastroenterol. 2012 Dec 14;18(46):6693-700. doi: 10.3748/wjg.v18.i46.6693.


  302. Changes in expression of the chloride homeostasis-regulating genes, KCC2 and NKCC1, in the blood of cirrhotic patients with hepatic encephalopathy
    Li JJ, Ji R, Shi YQ, Wang YY, Yang YL, Dou KF. Exp Ther Med. 2012 Dec;4(6):1075-1080. Epub 2012 Sep 24.


  303. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study
    Merli M, Giusto M, Lucidi C, Giannelli V, Pentassuglio I, Di Gregorio V, Lattanzi B, Riggio O. Metab Brain Dis. 2012 Dec 7. [Epub ahead of print]
 
 
                               
 
HBV
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
 
HE
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
OTHER
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
CLDF Sponsors & Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2019 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.